Reported 1 day ago
Analysts are showing bullish sentiment towards Soleno Therapeutics (NASDAQ:SLNO) following a positive fiscal update highlighting the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome. With significant interest evidenced by 646 patient start forms from multiple prescribers, the company is also pursuing EU marketing approval. Analysts from TD Cowen and Oppenheimer maintain strong Buy ratings with price targets of $120 and $110, respectively, indicating confidence in SLNO's future performance.
Source: YAHOO